Advertisement
Advertisement
TOPIC
 / company

BeOne

BeOne
The latest news and top stories on BeOne Medicines. Hong Kong-listed BeOne Medicines, formerly BeiGene, specialises in developing and selling innovative oncology products. Headquartered in Beijing China with global operations, they primarily serve cancer patients worldwide, addressing unmet medical needs. Notable for its rapid growth and pioneering advancements in immuno-oncology, the company's key products include the blood cancer drug zanubrutinib (Brukinsa) and the oncology drug tislelizumab (Tevimbra). BeOne Medicines anticipates significant net profit, reflecting its focus on transforming cancer treatment through cutting-edge research and global expansion.
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

China’s biotech boom drives surge in home-grown innovative drug approvals

Hang Seng Index review to boost market capitalisation by 4.5%: analysts

videocam

China AI firms Zhipu, MiniMax to join Hong Kong’s Hang Seng Tech Index

Additions to the benchmark Hang Seng Index, meanwhile, increase the number of constituents to 93 as the bourse operator presses ahead with expansion to 100.

videocam
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement